# First demonstration of the circulation of a pneumovirus in French pigs by detection of anti-swine orthopneumovirus nucleoprotein antibodies

Charles-Adrien Richard, Caroline Hervet, Déborah Ménard, Irina Gutsche, Valérie Normand, Fanny Renois, François Meurens, Jean Francois Eléouët

<figure><img src="image_1.png" /></figure>

## ► To cite this version:

Charles-Adrien Richard, Caroline Hervet, Déborah Ménard, Irina Gutsche, Valérie Normand, et al. First demonstration of the circulation of a pneumovirus in French pigs by detection of anti-swine orthopneumovirus nucleoprotein antibodies. BMC Veterinary Research, 2018, 49 (1), 10.1186/s13567-018-0615-x. hal-01964289

HAL Id: hal-01964289

https://hal.science/hal-01964289

Submitted on 21 Dec 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

<figure><img src="image_2.png" /></figure>
<figure><img src="image_3.png" /></figure>

RESEARCH ARTICLE

Open Access

<figure><img src="image_4.png" /></figure>

CrossMark

# First demonstration of the circulation of a pneumovirus in French pigs by detection of anti-swine orthopneumovirus nucleoprotein antibodies

Charles-Adrien Richard<fnref n="1" />†, Caroline Hervet²†, Déborah Ménard², Irina Gutsche³, Valérie Normand⁴, Fanny Renois², François Meurens² and Jean-François Eléouët<fnref n="1" />*

## Abstract

The presence of pneumoviruses in pigs is poorly documented. In this study, we used the published sequence of the nucleoprotein (N) of the recently identified Swine Orthopneumovirus (SOV) to express and purify SOV N as a recombinant protein in Escherichia coli. This protein was purified as nanorings and used to set up an enzyme-linked immunosorbent assay, which was used to analyse the presence of anti-pneumovirus N antibodies in swine sera. Sera collected from different pig farms in the West of France and from specific pathogen free piglets before colostrum uptake showed indirectly that a pneumovirus is circulating in pig populations with some variations between animals. Piglets before colostrum uptake were sero-negative for anti-pneumovirus antibodies while most of the other pigs showed positivity. Interestingly, in two farms presenting respiratory clinical signs and negative or under control for some common respiratory pathogens, pigs were detected positive for anti-pneumovirus antibodies. Globally, anti-pneumovirus N antibody concentrations were variable between and within farms. Further studies will aim to isolate the circulating virus and determine its potential pathogenicity. SOV could potentially become a new member of the porcine respiratory complex, important on its own or in association with other viral and bacterial micro-organisms.

## Introduction

Recently, the former paramyxoviral subfamily Pneumovirinae was elevated to family status Pneumoviridae [1–3]. This new family is composed of the two genus Metapneumovirus and Orthopneumovirus. Seven different viruses have been identified in several animal species as belonging to this family: avian metapneumovirus (AMPV) and human metapneumovirus (HMPV) for the Metapneumovirus genus, bovine respiratory syncytial virus (BRSV), ovine respiratory syncytial virus (ORV), human respiratory syncytial virus (HRSV), pneumonia virus of mice

(PVM), and canine pneumovirus (CPV) for the Orthopneumovirus genus. More recently, an eighth pneumovirus was identified by metagenomic sequencing of pooled nasal swabs in feral swine in the USA [4]. This newly identified Orthopneumovirus shows 93% and 91% protein identities with PVM and CPV, respectively, and was named swine Orthopneumovirus (SOV). Since no specific enzyme-linked immunosorbent assay (ELISA) is available for SOV, based on the close genetic relationship between PVM and SOV Hause et al. used a commercial ELISA to detect antibodies to PVM and found that 31% of the analysed feral swine sera were antibody positive [4]. Finally, analyses by the same PVM ELISA of sera from different American farms revealed that sera were 33% to 93% positive, dependent on the farms, and confirmed that SOV is also present in domestic swine. Interestingly, using bovine respiratory syncytial virus antigens, in 1998 Allan

<footnote>*Correspondence: Jean-francois.eleouet@inra.fr</footnote>

<footnote>†Charles-Adrien Richard and Caroline Hervet contributed equally to this work</footnote>

<footnote n="1">¹Unité de Virologie et Immunologie Moléculaires, INRA, Université Paris-Saclay, 78350 Jouy-en-Josas, France</footnote>

<footnote>Full list of author information is available at the end of the article</footnote>
et al. found that 41% of pigs sera from 61 herds in Northern Ireland were reactive with BRSV antigens [5].

Although SOV has not yet been isolated, the complete genomic sequence of SOV (strain 57) is available (Gen-Bank accession number: KX364383.1). We thus used the published sequences to synthesize expression vectors for nucleoprotein (N) and phosphoprotein (P) in order to express these proteins in bacteria. As developed previously with HRSV [6], co-expression of the C-terminal region of SOV P fused to GST together with SOV N allowed us to purify SOV N nanorings. These N nanorings were used further to develop an ELISA in order to detect the presence of anti-pneumovirus N antibodies in domestic pigs in the West of France.

## Materials and methods

### Expression and purification of recombinant SOV nucleoprotein

The full-length SOV N and P coding sequences (Gen-Bank accession number: KX364383.1) were synthesized for optimized expression in *Escherichia coli* (Genscript). Our previous studies with respiratory syncytial virus showed that the P C-terminal disordered region (PCT, amino acid residues 161–241, Figure 1) fused to GST is very efficient for purifying HRSV N protein after co-expression in *E. coli* [6]. The same approach was applied to SOV. First, the C-terminal disordered region of SOV P (amino acid residues 208–295) was determined by alignment with HRSV P (Figure 1).

The identified region of SOV P was amplified by PCR and subcloned in pGEX-4T-3 at BamHI-XhoI sites to engineer the pGEX-PCT vector. SOV N gene was subcloned in pET28a+ at NdeI-XhoI sites to engineer the pET-N vector. *E. coli* BL21 (DE3) (Novagen) cells were co-transformed with the pGEX-PCT and pET-N plasmids and were grown at 37 °C for 8 h in 1 L of Luria-Bertani (LB) medium containing 100 µg/mL ampicillin and 50 µg/mL kanamycin. The same volume of fresh LB was then added, and protein expression was induced by adding isopropyl-β-D-thio-galactoside (IPTG) to the medium (final concentration 0.33 mM). Bacteria were grown at 28 °C and harvested by centrifugation 15 h after induction. Bacterial pellets were re-suspended in lysis buffer (50 mM Tris-HCl pH 7.8, 60 mM NaCl, 1 mM EDTA, 2 mM DTT, 0.2% Triton X-100, 1 mg/L lysozyme) supplemented with complete protease inhibitor cocktail (Roche, Mannheim, Germany) and incubated for 1 h on ice, sonicated, and centrifuged at 4 °C for 30 min at 10 000 × g. Glutathione-Sepharose 4B beads (GE Healthcare, Uppsala, Sweden) were added to clarified supernatants and incubated at 4 °C for 15 h. Beads were then washed two times in lysis buffer and three times in PBS 1X, then stored at 4 °C in an equal volume of PBS. To isolate PCT-N complexes, beads were resuspended in an equal volume of PBS+1 mM DTT and incubated with biotinylated thrombin (Novagen) for 16 h at 20 °C. Thrombin was then removed using the Thrombin cleavage capture kit according to

<figure><img src="image_5.png" /><figcaption>**Figure 1** Amino acid sequence alignments between full-length SOV (strain 57) and human RSV (HRSV, strain Long VR-26) P proteins.</figcaption></figure>

Invariant residues are highlighted in white font on a red background. The C-terminal region of HRSV P identified previously as an N-RNA binding region (residues 161–241) and the corresponding region for SOV P (residues 208–295) are boxed in blue. Genbank accession codes: ANO40516.1 (SOV P) and AHC94770.1 (HRSV). Sequences were aligned with Clustal W and treated with ESPript 3.
the manufacturer's instructions (Novagen). Purified complexes were run in polyacrylamide gels stained with Coomassie blue.

## Negative stain electron microscopy observations of recombinant SOV nucleoprotein

Three microliter of sample were applied to the clean side of carbon on a carbon–mica interface and stained with 2% sodium silicotungstate. Micrographs were recorded on a FEI Tecnai T12 microscope operated at 120 kV with a Gatan Orius 1000 camera. Images were recorded at a nominal magnification of 23 000 × resulting in a pixel size of 2.8 Å.

## Serum samples

**Positive standards:** Sera obtained from different pig farms located in the West of France were used to search for positive reactions to SOV nucleoprotein. Sera with an optical density (OD) superior to 3.5 were selected as positive standards. Amongst these sera, one with intermediate OD was used to make serial dilutions (1/50, 1/75,

1/100, 1/200, 1/400, 1/800, 1/600, 1/3200, and 1/6400) and generate a standard curve. Then, two additional sera with extremely high OD were also assessed to generate potential standard curves.

## Negative standards

Sera from newborn specific pathogen free piglets (SPF), just before colostrum uptake, generously provided by Anses Ploufragan (France), were used as negative controls (Table 1). SPF sows from Anses are originally delivered by cesarean section in germ free conditions. Then, sows and their piglets are routinely tested by ELISA (serology) and PCR assays against various pathogens (porcine circoviruses, influenza viruses, Aujeszky disease virus, *Mycoplasma hyopneumoniae*, *Haemophilus parasuis*, *Actinobacillus pleuropneumoniae*, porcine reproductive and respiratory syndrome virus, *Pasteurella multocida*, *Bordetella bronchiseptica*, *Streptococcus suis* type 1 and 2, *Salmonella* spp. and others) to confirm their SPF status at Anses high containment pig research facilities.

<table><caption>Table 1 Information about the different pig farms assessed in the study (– negative, + positive)</caption><thead><tr><th>Farms</th><th>Anses-<br>SPF<br>piglets<sup>a</sup></th><th>A</th><th>B</th><th>B</th><th>C</th><th>C</th><th>D</th><th>E</th></tr></thead><tbody><tr><td>Age of selected<br>pigs (days)</td><td>0</td><td>150</td><td>84</td><td>105</td><td>91</td><td>105</td><td>160</td><td>150</td></tr><tr><td>Number of<br>animals</td><td>5</td><td>10</td><td>15</td><td>12</td><td>10</td><td>8</td><td>15</td><td>8</td></tr><tr><td>Respiratory<br>symptoms<br>identified in<br>the farm</td><td>No</td><td>Yes</td><td>Yes</td><td>Yes</td><td>±</td><td>±</td><td>No</td><td>Yes</td></tr><tr><td colspan="9">Respiratory symptoms observed on the batch (Post-weaning or fattening period)</td></tr><tr><td>Cough</td><td>No</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>Dyspnoea</td><td>No</td><td>Yes</td><td>Yes</td><td>Yes</td><td>No</td><td>No</td><td>No</td><td>Yes</td></tr><tr><td>Sneezing</td><td>No</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>PRRSV in the<br>farm</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>Yes</td></tr><tr><td>Mycoplasma<br>hyopneumo-<br>niae in the<br>farm</td><td>No</td><td>Vaccinated</td><td>Vaccinated</td><td>Vaccinated</td><td>Vaccinated</td><td>Vaccinated</td><td>No</td><td>Vaccinated</td></tr><tr><td>Influenza virus<br>isolation in<br>post-weaning</td><td>No</td><td>H1N2<br>April 2015</td><td></td><td></td><td>ND</td><td>ND</td><td>No</td><td>ND</td></tr><tr><td>Influenza status<br>of the batch</td><td>–</td><td>+</td><td>+</td><td>+</td><td>ND</td><td>ND</td><td>–</td><td>ND</td></tr><tr><td>Actinobacillus<br>pleuropneu-<br>moniae</td><td>–</td><td>No specific<br>lesions</td><td>No specific<br>lesions</td><td>No specific<br>lesions</td><td>No specific<br>lesions</td><td>No specific<br>lesions</td><td>Free for all<br>serot-<br>pyes</td><td>No specific<br>lesions</td></tr><tr><td>SOV serology</td><td>–</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td></tr></tbody></table>

ND: not documented.

<footnote><sup>a</sup> Newborn piglets before colostrum uptake.</footnote>
All the other tested sera were obtained during routine prophylactic monitoring from five different pig farms (A–E) all located in the West of France (Table 1). In three farms (A, B, and E) clinical signs such as coughing, sneezing, and high respiratory frequency were clearly identified in most of the pigs. In one farm (D), faint clinical signs such as coughing were reported in some pigs.

To optimize the reading of every OD, sera were diluted 1/800 as validated from the dilution range analysis (Additional file 1). ELISA to detect the presence of antibodies porcine reproductive and respiratory syndrome virus (PRRSV) (IDEXX Montpellier SAS, Montpellier, France) and *Mycoplasma hyopneumoniae* (IDEXX and Oxoid-ThermoFisher Scientific), two major porcine respiratory pathogens [7], had been performed previously to assess the status of the selected pig farms. Porcine influenza is endemic in most of the French pig farms [8, 9] and the virus was either isolated, not sought or absent. Regarding *Actinobacillus pleuropneumoniae*, specific lesions were sought and in one farm serology to all commonly circulating serotypes assessed. All the pigs were routinely followed by veterinarians for clinical signs of respiratory infection (coughing and increased respiratory frequency amongst others). To test cross-reactivity with BRSV, porcine sera were assessed with IDEXX RSV IgG Ab Test, a commercial ELISA developed to detect IgG targeting BRSV in bovine sera. The six porcine sera with the highest OD in our ELISA and the seven sera with lowest OD were used for the bovine ELISA. As positive and negative controls, bovine sera positive and negative for anti-RSV IgG, generously provided by large animal clinic (Dr Sebastien Assié, Oniris), were used. Then, the same bovine samples were tested in our next described anti-SOV ELISA.

## Enzyme-linked immunosorbent assays

Swine orthopneumovirus specific antibodies were detected using an ELISA with SOV N as target antigen. Optimal concentrations of the antigen and the enzyme conjugated secondary antibody were defined after testing different conditions as specified in the recommendations for standardization and validation of ELISA assay [2]. ELISA plates (NUNC 96, ThermoFisher Scientific, Illkirch, France) were coated overnight at 4 °C with SOV N (15 µg/mL) in carbonate buffer (0.1 M, pH 9.5, 100 µL/well). The plates were then washed twice for 5 min with phosphate-buffered saline (PBS) containing 1% Tween 20 (Sigma-Aldrich Chimie, Saint-Quentin Fallavier) (PBST) and blocked by an incubation with 130 µL/well of 2% gelatin (Bio-Rad, Marnes-la-Coquette, France) in carbonate buffer (0.1 M, pH 9.5) for 30 min at 37 °C. After this incubation, the liquid was discarded and plates were washed twice with PBST. Then, 100 µL of each serum

sample, serially diluted in PBST to dilution 1/800, was added (in duplicate) and incubated at 37 °C for 1 h. Subsequently, the plates were washed twice with PBST and incubated for 1 h at 37 °C with 100 µL/well of goat anti pig IgG conjugated to horseradish peroxidase (Goat anti Pig IgG (Fc): HRP ref AAI41P) (Bio-Rad) at 0.1 µg/mL diluted in PBST. Then, the plate was washed twice with PBST and twice with PBS. Substrate solution, TMB signal + (Bio-Rad) was subsequently added (100 µL/well) and the plate was incubated at 22–27 °C for 20 min. The reaction was stopped by the addition of 100 µL H₂SO₄ 0.2 M to each well (Sigma-Aldrich Chimie). Optical densities (OD) were measured at 450 nm using a microplate reader (ThermoFisher Scientific Multiskan GO 1.01.10).

## Results

### Purification and characterization of recombinant SOV N protein

We previously developed a protocol to purify HRSV N protein as nanorings containing 10 or 11 N protomers and 70 or 77 bases in length RNA, respectively [6, 10]. HRSV P is composed of a N-terminal disordered region (residues 1–125), a central tetramerization domain (residues 126–160) and a C-terminal disordered region (residues 161–241) [11]. The C-terminal region of HRSV P (PCT) fused to GST was found highly efficient for purifying RSV N from *E. coli*. In order to apply this technique to SOV, we aligned HRSV and SOV P protein sequences to define the corresponding regions of SOV P. Thanks to sequence homologies between HRSV and SOV P, the SOV P region extending from amino acid residues 208 to 295 (MW~10 kDa) was identified as the C-terminal disordered and N-binding region of P (Figure 1). This SOV PCT region was fused to GST in the pGEX-4T-3 vector and co-expressed in *E. coli* together with the pET-28-N vector. As shown in Figure 2, SOV N and GST-PCT were purified to >95% homogeneity. SOV N, migrating with apparent MW of 43 kDa, as expected, was recovered as a soluble protein after thrombin cleavage of the GST-PCT/N complexes bound to glutathione-Sepharose beads.

When using a similar technique, HRSV N protein is recovered as rings containing either 10 or 11 N protomers and with a diameter of ~15–20 nm [6, 10]. To determine whether SOV N was also composed of nanorings, purified complexes were analysed by size-exclusion chromatography on a Sephacryl S-200 column (GE Healthcare) and the collected fractions were analysed by SDS-PAGE and Coomassie blue staining. The first peak (P1) eluted at 23 mL, with absorption detected at both 220, 260 and 280 nm, and contained exclusively the SOV N protein (Figure 3). Since the UV absorption was higher at 260 nm than 280 nm, these data indicated that RNA was present
<figure><img src="image_6.png" /></figure>

in the N fraction. The size of this complex was estimated to be approximately 530 kDa, indicating that N was present as oligomers. The second peak (P2) only absorbed at 220 nm and contained the PCT fragment. Its apparent mass was comprised between 25 and 43 kDa, higher than its predicted mass of 10 kDa, presumably due to a markedly non-globular shape of the P fragment.

The SOV N protein purified by gel filtration was analysed by negative stain electron microscopy. A representative micrograph, shown in Figure 4, confirmed that SOV N was recovered as nanorings with a diameter of ~15 nm.

## Detection of anti-pneumovirus antibodies in French swine herds using SOV N protein

The recombinant SOV N was then used to develop an ELISA in order to detect antibodies targeting pneumovirus N in some French pig farms. ELISA was optimized and the 1/800 dilution, still in the linear phase of the standard curve (Additional file 1) as recommended [2], was ultimately selected. Indeed, the 1/400 dilution generated too many samples with very OD and was not further

used (Additional file 2). Additional standard curves generated from subsequent samples with higher OD needed extremely high dilutions to linearize the signal and were not selected for following analyses (Additional file 3).

Specific pathogen free piglets before colostrum uptake were sero-negative for anti-pneumovirus N antibodies. On the contrary, most of the sera collected from pigs raised in five different farms from the West of France that were routinely monitored for respiratory infectious diseases (see Table 1) showed positivity to various levels (Figure 5). Variations between pigs positive for anti-pneumovirus N antibodies was significant with OD ranging between 0.47 and 3.52 (dilution 1/800). Three sera presented very high OD values and ideally should have been further diluted, at least two folds, before being tested. Interestingly, a herd (C) negative for PRRSV, without *A. pleuropneumoniae* specific lesions, and presenting mild respiratory symptoms was positive for anti-pneumovirus N antibodies (Figure 5 and Table 1). However, influenza virus status was not determined for this farm (Figure 5).

Cross reactivity tests based on porcine sera tested with the BRSV ELISA and bovine sera tested with our pig ELISA showed absence of cross-reactivity of the antibodies. Indeed, porcine sera tested with the BRSV ELISA could be considered negative for anti-BRSV antibodies (see Figure 6) and strongly positive bovine sera for BRSV had OD values < 0.005 when tested with our new ELISA.

## Discussion

The presence of pneumoviruses in swine is poorly documented. Recently a newly discovered swine pneumovirus (SOV) was identified by metagenomic sequencing of pooled nasal swabs in feral swine in USA [4]. Sequence comparison with other members of the *Pneumoviridae* family showed that SOV is closely related to PVM and CPV. For example, amino acid sequence identities between SOV and other pneumoviruses N proteins are of 97.5% for PVM, 97.5% for CPV, 59.8% for HRSV, 60% for BRSV, 45.7% for HMPV, and 43.3% for AMPV, respectively. However, SOV has not been isolated yet and it is completely unknown whether this virus is pathogenic.

Although a study performed by Allan et al. in 1998 showed that 41% of pigs sera from 61 herds in Northern Ireland were reactive with BRSV antigens [5], thus suggesting the presence of pneumovirus in swine, this kind of study has not been carried out in other European countries yet. The aim of this work was to investigate the presence of pneumovirus in French swine. Among pneumovirus proteins, the N protein is highly conserved between strains and, as an example, for HRSV it was shown to be highly immunogenic either by natural infection [12] or by administration [13–18]. RSV N protein
<figure><img src="image_7.png" /></figure>

<figure><img src="image_8.png" /><figcaption>**Figure 3** Elution profile of the PCTD + N complexes. A</figcaption></figure>

Absorbances were monitored at 280 nm (blue line), 260 nm (red line) and 220 nm (gray line). Samples (3 mL) were filtered through a 0.22 µm pore-size filter and run on a Sephadryl S200 column and fractions of 1 mL were collected. The following size markers (GE Healthcare) were used to calibrate the column (mass in parentheses): 1, ribonuclease A (13 700); 2, chymotrypsinogen A (20 200); 3, ovalbumin (47 200); 4, albumin (61 000); 5, catalase (232 000); 6, ferretin (440 000); 7, thyroglobulin (699 000). V, Void volume; T, total volume of the column. B, The indicated fractions were analyzed by SDS-PAGE as described in Figure 2.

<figure><img src="image_9.png" /><figcaption>**Figure 4** A typical negative stain electron microscopy image of recombinant SOV N after purification by gel filtration. Scale bar, 100 nm.</figcaption></figure>

<figure><img src="image_10.png" /><figcaption>**Figure 5** SOV N ELISA results. Optical density (OD) was varying between herds with some specific pathogen free piglets before colostrum uptake staying free of anti-pneumovirus antibodies. Dilution 1/800 was selected for the analysis. The characteristics of the selected pig farms are presented in Table 1.</figcaption></figure>

has also been used to develop RSV specific ELISAs [12–18]. Using the recently published sequence of SOV, we engineered and purified recombinant and soluble SOV N protein from *E. coli*. Like observed previously with HRSV [6], SOV N protein produced in bacteria forms soluble nanorings containing nucleic acids that can be purified to >95% homogeneity by using the C-terminal region of SOV P fused to GST. Like for HRSV [10], the SOV nanorings were composed of two major populations with an average diameter of ~15 nm, which correspond to the

diameter of the left-handed helical nucleocapsid of pneumoviruses [10, 19, 20]. Although we have no explanation for the presence of nanorings only and the absence of helical structures in this system, these nanorings must be formed thanks to the elasticity of N oligomers, the absence of other factors such as full length P, and N–N interactions occurring after one helix turn and closing the ring structure.

Swine orthopneumovirus N nanorings were then used to develop an anti-pneumovirus N ELISA. Our results revealed indirectly a significant circulation of a pneumovirus between pigs within selected pig farms in the West of France and an absence of anti-pneumovirus antibodies
BRSV ELISA

<figure><img src="image_11.png" /></figure>

Porcine and bovine sera

**Figure 6** Commercial BRSV ELISA results. Selected porcine and bovine sera were tested for the presence of anti-BRSV antibodies. S/P% = 100 × (NE/NExpc). NE: Net Extinction value for each sample was calculated by subtracting the OD450 value of the control well (S-Ag A450) from the OD450 value of the coated well (S + Ag A450) as recommended by the provider.

in SPF piglets. Results in these SPF piglets could be used
to estimate the cut-off value for negativity around OD 0.5
even if it must be further confirmed by future research
with experimental inoculation of the virus to fully naïve
pigs. Moreover, seronegativity of SPF piglets is also an
interesting observation as it shows an absence of cross-
reactivity of our ELISA test to porcine plasmatic proteins.
Then, the absence of cross-reactivity with BRSV allowed
us to exclude the potential circulation of a bovine pneu-
movirus in pigs. However cross-reactivity with other
pneumoviruses should also be tested. Indeed, pneu-
movirus N proteins present strong similarities between
pneumoviruses. Our cross-reactivity test results could
seem contradictory with the study from Allan et al. [5].
This discrepancy might be explained by the use of vari-
ous BRSV ELISA (differences in the conformation of the
selected antigen and sensitivity for instance). The detec-
tion of anti-pneumovirus N antibodies in one farm (C)
negative for PRRSV, under vaccination control for M.
hyopneumoniae, and most probably negative for A. pleu-
ropneumoniae but still presenting respiratory symptoms
might suggest a potential pathogenicity of SOV in pigs,
in association or not with other member of the porcine
respiratory complex (PRC). The situation in farms A and
B, showing similar respiratory pathogen profile to that
of farm C but where influenza virus had been detected
before might also support to some extent that hypothesis.

However, since many other pathogens are involved in
the PRC and because of the absence of clinical data col-
lected for every individual pig in our study, there is an
urgent need for further research before being able to
formulate strong conclusions regarding SOV potential
pathogenicity.

In summary, this work is the first one showing that a
pneumovirus is present or had circulated in some French
pig farms. Future prospects will be needed to give a
more complete image of the percentage of positive pigs
in French farms. However, it is currently completely
unknown whether SOV is pathogenic or not for pigs.
Future isolation of SOV and experimental animal infec-
tions are needed to allow deep characterization of the
porcine pneumovirus and the determination of its patho-
genicity in various conditions. SOV could also represent
a new animal model for pneumovirus infection [21].

**Additional files**

**Additional file 1. Serum dilution range of the SOV N ELISA.** Serum dilution 1/800 were ultimately selected for antibody detection.

**Additional file 2. SOV N ELISA results using dilution 1/400.** Optical density (OD) was varying between herds with some specific pathogen free piglets before colostrum uptake staying free of anti-pneumovirus antibodies.

**Additional file 3. Standard curves generated from highest OD samples (green and brown lines) were compared to the selected standard curve (blue line).** Dilutions of the negative standard is presented in red.

**Abbreviations**

AMPV: avian metapneumovirus; CPV: canine pneumovirus; ELISA: enzyme linked immuno sorbent assay; GST: glutathione-S-transferase; HMPV: human metapneumovirus; PVM: pneumonia virus of mice; MW: molecular weight; N: nucleoprotein; OD: optical density; P: phosphoprotein; PCT: phosphoprotein C-terminal region; PRRSV: porcine reproductive and respiratory syndrome virus; RSV: respiratory syncytial virus; SOV: swine orthopneumovirus; TBE: Tris-borate-EDTA buffer.

**Competing interests**

The authors declare that they have no competing interests.

**Authors' contributions**

JFE supervised the project and conceived part of the experiments. FM supervised ELISA development. IG, FM, FR, CAR and JFE analysed the data and drafted the manuscript. CH carried out most of the experiments related to the ELISA development. CAR, CH, DM, VN, and IG performed part of the experiments. All authors read and approved the final manuscript.

**Acknowledgements**

We acknowledge the usage of the electron microscope of the dedicated platform of the Grenoble Instruct center (ISBG; UMS 3518 CNRS-CEA-UGA-EMBL) with support from FRISBI [Agence Nationale de la Recherche (ANR)] (ANR-10-INSB-05-02) and GRAL (ANR-10-LABX-49-01) within the Grenoble Partnership for Structural Biology (PSB). The electron microscope facility is supported by the Rhône-Alpes Region, the Fondation pour la Recherche Médicale (FRM), the fonds FEDER, the Centre National de la Recherche Scientifique (CNRS), the Commissariat à l'Énergie Atomique et aux Energies Alternatives (CEA), the University of Grenoble Alpes, EMBL, and the GIS-Infrastructures en Biologie
Santé et Agronomie (IBISA). FM is supported by an establishment grant from the Région Pays de la Loire (RFI Food for tomorrow-Cap aliment). This lab work was carried out with the financial support of the regional programme "Food for Tomorrow/Cap Aliment; Research, Education and Innovation in Pays de la Loire", which is supported by the French Region Pays de la Loire and the European Regional Development Fund (FEDER). Thanks also to Prof. Alain Chauvin and Daniel Hogan for their helpful comments.

Author details

¹ Unité de Virologie et Immunologie Moléculaires, INRA, Université Paris-Saclay, 78350 Jouy-en-Josas, France. ² BIOEPAR, INRA, Oniris, Université Bretagne Loire, 44307 Nantes, France. ³ CNRS, CEA, IBS, University of Grenoble Alpes, 38000 Grenoble, France. ⁴ Porc.Spective Swine Vet Practice, Chêne Vert Conseil Veterinary Group, ZA de Gohéléve, 56920 Noyal-Pontivy, France.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 1 October 2018 Accepted: 29 November 2018

Published online: 05 December 2018

References

1. Afonso CL, Amarasinghe GK, Banyai K, Bao Y, Basler CF, Bavari S, Bejerman N, Blasdell KR, Briand FX, Briese T, Bukreyev A, Calisher CH, Chandran K, Cheng J, Clawson AN, Collins PL, Dietzgen RG, Dolnik O, Domier LL, Durwald R, Dye JM, Easton AJ, Ebihara H, Farkas SL, Freitas-Astua J, Formenty P, Fouchier RA, Fu Y, Ghedin E, Goodin MM et al. (2016) Taxonomy of the order Mononegavirales: update 2016. Arch Virol 161:2351–2360

2. Wright PF, Nilsson E, Van Rooij EM, Lelenta M, Jego MH (1993) Standardisation and validation of enzyme-linked immunosorbent assay techniques for the detection of antibody in infectious disease diagnosis. Rev Sci Tech 12:435–450

3. Rima B, Collins P, Easton A, Fouchier R, Kurath G, Lamb RA, Lee B, Maisner A, Rota P, Wang L, Ictv Report Consortium (2017) ICTV virus taxonomy profile: Pneumoviridae. J Gen Virol 98:2912–2913

4. Hause BM, Padmanabhan A, Pedersen K, Gidlewski T (2016) Feral swine virome is dominated by single-stranded DNA viruses and contains a novel *Orthopneumovirus* which circulates both in feral and domestic swine. J Gen Virol 97:2090–2095

5. Allan GM, McNeilly F, Walker IW, Young JA, Fee S, Douglas AJ, Adair BM (1998) Serological evidence for pneumovirus infections in pigs. Vet Rec 142:8–12

6. Tran TL, Castagne N, Bhella D, Varela PF, Bernard J, Chilmonczyk S, Berkenkamp S, Benhamo V, Grznarova K, Grosclaude J, Nespoulos C, Rey FA, Eleouet JF (2007) The nine C-terminal amino acids of the respiratory syncytial virus protein P are necessary and sufficient for binding to ribonucleoprotein complexes in which six ribonucleotides are contacted per N protein protomer. J Gen Virol 88:196–206

7. Fablet C, Marois-Crehan C, Simon G, Grasland B, Jestin A, Kobisch M, Madec F, Rose N (2012) Infectious agents associated with respiratory diseases in 125 farrow-to-finish pig herds: a cross-sectional study. Vet Microbiol 157:152–163

8. Cador C, Andraud M, Willem L, Rose N (2017) Control of endemic swine flu persistence in farrow-to-finish pig farms: a stochastic metapopulation modeling assessment. Vet Res 48:58

9. Simon-Grife M, Martin-Valls GE, Vilar MJ, Busquets N, Mora-Salvatierra M, Besteiro TM, Fouchier RA, Martin M, Mateu E, Casal J (2012) Swine influenza virus infection dynamics in two pig farms; results of a longitudinal assessment. Vet Res 43:24

10. Tawar RG, Duquerroy S, Vonrhein C, Varela PF, Damier-Piolle L, Castagne N, MacLellan K, Bedouelle H, Bricogne G, Bhella D, Eleouet JF, Rey FA (2009) Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science 326:1279–1283

11. Pereira N, Cardone C, Lassoued S, Galloux M, Fix J, Assrir N, Lescop E, Bontems F, Eleouet JF, Sizun C (2017) New insights into structural disorder in human respiratory syncytial virus phosphoprotein and implications for binding of protein partners. J Biol Chem 292:2120–2131

12. Zhang Y, Brooks WA, Goswami D, Rahman M, Luby SP, Erdman DD (2014) A duplex recombinant viral nucleoprotein microbead immunoassay for simultaneous detection of ser responses to human respiratory syncytial virus and metapneumovirus infections. J Virol Methods 206:55–62

13. Roux X, Dubuquoy C, Durand G, Tran-Tolla TL, Castagne N, Bernard J, Petit-Camurdan A, Eleouet JF, Riffault S (2008) Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus. PLoS One 3:e1766

14. Riffault S, Meyer G, Deplanche M, Dubuquoy C, Durand G, Soulestin M, Castagne N, Bernard J, Bernardet P, Dubosclard V, Bernex F, Petit-Camurdan A, Deville S, Schwartz-Cornil I, Eleouet JF (2010) A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus. Vaccine 28:3722–3734

15. Blodorn K, Hagglund S, Fix J, Dubuquoy C, Makabi-Panzu B, Thom M, Karlsson P, Roque JL, Karlstam E, Pringle J, Eleouet JF, Riffault S, Taylor G, Valarcher JF (2014) Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies. PLoS One 9:e100392

16. Herve PL, Raliou M, Bourdieu C, Dubuquoy C, Petit-Camurdan A, Bertho N, Eleouet JF, Chevalier C, Riffault S (2014) A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2. J Virol 88:325–338

17. Herve PL, Descamps D, Deloizy C, Dhelft V, Laubreton D, Bouguyon E, Boukadiri A, Dubuquoy C, Larcher T, Benhamou PH, Eleouet JF, Bertho N, Mondoulet L, Riffault S (2016) Non-invasive epicutaneous vaccine against respiratory syncytial virus: preclinical proof of concept. J Control Release 243:146–159

18. Herve PL, Deloizy C, Descamps D, Rameix-Welti MA, Fix J, McLellan JS, Eleouet JF, Riffault S (2017) RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine. Nanomedicine 13:411–420

19. Bakker SE, Duquerroy S, Galloux M, Loney C, Conner E, Eleouet JF, Rey FA, Bhella D (2013) The respiratory syncytial virus nucleoprotein-RNA complex forms a left-handed helical nucleocapsid. J Gen Virol 94:1734–1738

20. Liljeroos L, Krzyzaniak MA, Helenius A, Butcher SJ (2013) Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci U S A 110:11133–11138

21. Meurens F, Summerfield A, Nauwynck H, Saif L, Gerdts V (2012) The pig: a model for human infectious diseases. Trends Microbiol 20:50–57

Ready to submit your research? Choose BMC and benefit from:

* fast, convenient online submission

* thorough peer review by experienced researchers in your field

* rapid publication on acceptance

* support for research data, including large and complex data types

* gold Open Access which fosters wider collaboration and increased citations

* maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

<figure><img src="image_12.png" /></figure>